Cell Therapy Technologies Market based on By Therapy Type (Autologous, Allogenic), By Therapeutic Area (Oncology, CVD, Dermatology), By Region - Global Forecast up to 2030
Cell therapy is important in giving diagnostic and prognostic information for a variety of disorders, including HIV/AIDS, cancer, and infectious diseases. It helps academics and healthcare practitioners to acquire insights into disease causes, illness development, and therapy responses using novel cellular-based techniques. Global population expansion, climate change, and greater human-animal interaction have produced an environment conducive to the genesis of novel viral epidemics. Cell therapy research and applications are critical in tackling these issues because they provide enhanced diagnostic tools, therapeutic approaches, and a better knowledge of disease causes.
Cell biology research is primarily concerned with the development of novel medicines such as stem cell and gene therapies. High-quality tools, reagents, and associated goods are required for reliable findings. Meeting regulatory rules and maintaining demanding quality standards in cell biology research, on the other hand, comes at a considerable expense. This is a problem for institutes and small businesses with limited funds, as they may be unable to acquire pricey research products.
Precision medicine is a developing approach to illness treatment and prevention that takes into account genetic, environmental, and lifestyle factors. It entails selecting drugs for each patient depending on their individual condition and medical history. Oncology has made significant advances in precision medicine, even as its use expands to diverse disorders. This personalised approach to diagnosis, treatment, and prevention makes better judgements by utilising full patient information such as genetics, environment, and lifestyle.
The segmentation coverage of the study is provided below.
Cell Therapy Technologies Market based on Therapy Type
It is divided into two types of therapies: autologous and allogenic. The market is divided by therapeutic areas such as malignancies, musculoskeletal diseases, autoimmune disorders, dermatology, and others. It is divided into two types of end-users: hospitals and clinics and academic and research institutes. The market is divided into four regions: North America (the United States, Canada, and Mexico), Europe (Germany, the United Kingdom, France, Spain, Italy, and the rest of Europe), Asia-Pacific (Japan, China, India, Australia, and the rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and the rest of LAMEA).
The hospitals and clinics category is expected to develop at the fastest CAGR throughout the projection period. The segment's profitable expansion may be linked to an increase in the number of pipeline developments over the last few years. According to CRI, the number of cell therapy treatment projects climbed from 753 in 2018 to 1,011 in 2019.
Due to population growth, a growing geriatric population, and increased awareness among healthcare entities and patients about the potential of these therapies in chronic disease management, Asia-Pacific presents lucrative opportunities for key players operating in the cell therapy market. Furthermore, rising healthcare expenditures and the development of guidelines are projected to drive market expansion in the area.
Kolon Tissue Gene, Inc., Osiris Therapeutics, Inc., JCR Pharmaceuticals Co. Ltd., NuVasive, Inc., Stemedica Cell Technologies, Inc., Cells for Cells, Holostem Terapie Avanzate S.r.l., Mesoblast Ltd., and Medipost Co., Ltd. are among the leading companies operating in the global cell therapy market.
Cell biology research is primarily concerned with the development of novel medicines such as stem cell and gene therapies. High-quality tools, reagents, and associated goods are required for reliable findings. Meeting regulatory rules and maintaining demanding quality standards in cell biology research, on the other hand, comes at a considerable expense. This is a problem for institutes and small businesses with limited funds, as they may be unable to acquire pricey research products.
Precision medicine is a developing approach to illness treatment and prevention that takes into account genetic, environmental, and lifestyle factors. It entails selecting drugs for each patient depending on their individual condition and medical history. Oncology has made significant advances in precision medicine, even as its use expands to diverse disorders. This personalised approach to diagnosis, treatment, and prevention makes better judgements by utilising full patient information such as genetics, environment, and lifestyle.
The segmentation coverage of the study is provided below.
Cell Therapy Technologies Market based on Therapy Type
- Allogeneic Therapies
- Stem Cell Therapies
- Hematopoietic Stem Cell Therapies
- Mesenchymal Stem Cell Therapies
- Non-Stem Cell Therapies
- Keratinocytes & Fibroblast-based Therapies
- Others
- Autologous Therapies
- Stem Cell Therapies
- BM, Blood, & Umbilical Cord-derived Stem Cells
- Adipose derived cells
- Others
- Non-Stem Cell Therapies
- T-Cell Therapies
- CAR T Cell Therapy
- T Cell Receptor (TCR)-based
- Oncology
- Cardiovascular Disease (CVD)
- Musculoskeletal Disorders
- Dermatology
- Others
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
It is divided into two types of therapies: autologous and allogenic. The market is divided by therapeutic areas such as malignancies, musculoskeletal diseases, autoimmune disorders, dermatology, and others. It is divided into two types of end-users: hospitals and clinics and academic and research institutes. The market is divided into four regions: North America (the United States, Canada, and Mexico), Europe (Germany, the United Kingdom, France, Spain, Italy, and the rest of Europe), Asia-Pacific (Japan, China, India, Australia, and the rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and the rest of LAMEA).
The hospitals and clinics category is expected to develop at the fastest CAGR throughout the projection period. The segment's profitable expansion may be linked to an increase in the number of pipeline developments over the last few years. According to CRI, the number of cell therapy treatment projects climbed from 753 in 2018 to 1,011 in 2019.
Due to population growth, a growing geriatric population, and increased awareness among healthcare entities and patients about the potential of these therapies in chronic disease management, Asia-Pacific presents lucrative opportunities for key players operating in the cell therapy market. Furthermore, rising healthcare expenditures and the development of guidelines are projected to drive market expansion in the area.
Kolon Tissue Gene, Inc., Osiris Therapeutics, Inc., JCR Pharmaceuticals Co. Ltd., NuVasive, Inc., Stemedica Cell Technologies, Inc., Cells for Cells, Holostem Terapie Avanzate S.r.l., Mesoblast Ltd., and Medipost Co., Ltd. are among the leading companies operating in the global cell therapy market.
- This report illustrates the most vital attributes of the Cell Therapy Technologies Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Cell Therapy Technologies Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Cell Therapy Technologies Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Cell Therapy Technologies Market.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. THERAPY TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Allogeneic Therapies
5.3. Autologous Therapies
6. THERAPEUTIC AREA: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oncology
6.3. Cardiovascular Disease (CVD)
6.4. Musculoskeletal Disorders
6.5. Dermatology
6.6. Others
7. GEOGRAPHY: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. North America (U.S., Mexico, Canada)
7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
7.5. Latin America (Brazil, Argentina)
7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
8. COMPETITIVE LANDSCAPE
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. VENDOR PROFILES
9.1. Novartis AG
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. Gilead Sciences, Inc.
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. Bristol-Myers Squibb Company
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. Johnson & Johnson Services, Inc
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. JCR Pharmaceuticals Co., Ltd.
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. Tego Science
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. Atara Biotherapeutics
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. Takeda Pharmaceutical Company Limited
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. Bluebird Bio, Inc.
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. Dendreon Corp.
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
10. ANALYST OPINION
11. ANNEXURE
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations
Tables
TABLE 1. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 2. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ALLOGENEIC THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR AUTOLOGOUS THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 5. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR CARDIOVASCULAR DISEASE (CVD), BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR DERMATOLOGY,2021-2030 (USD BILLION)
TABLE 9. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 11. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 14. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 15. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 16. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 17. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 18. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 19. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 20. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 21. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 22. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 23. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 24. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 25. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 26. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 27. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 28. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 29. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 30. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 31. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 32. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 33. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 34. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 35. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 36. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 37. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 38. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 39. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 40. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 41. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 42. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 43. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 44. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 45. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 46. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 47. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 48. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 49. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 50. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 51. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 52. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 53. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 54. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 55. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 56. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 57. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 58. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 59. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 60. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 61. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 62. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 63. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 64. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 65. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 66. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 67. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 68. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 69. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 70. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 71. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 72. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 73. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 74. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 75. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 76. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 77. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 78. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 79. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 80. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 81. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 82. NOVARTIS AG: FINANCIALS
TABLE 83. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 84. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 85. GILEAD SCIENCES, INC.: FINANCIALS
TABLE 86. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES
TABLE 87. GILEAD SCIENCES, INC.: RECENT DEVELOPMENTS
TABLE 88. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 89. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 90. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 91. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS
TABLE 92. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES
TABLE 93. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS
TABLE 94. JCR PHARMACEUTICALS CO., LTD.: FINANCIALS
TABLE 95. JCR PHARMACEUTICALS CO., LTD.: PRODUCTS & SERVICES
TABLE 96. JCR PHARMACEUTICALS CO., LTD.: RECENT DEVELOPMENTS
TABLE 97. TEGO SCIENCE: FINANCIALS
TABLE 98. TEGO SCIENCE: PRODUCTS & SERVICES
TABLE 99. TEGO SCIENCE: RECENT DEVELOPMENTS
TABLE 100. ATARA BIOTHERAPEUTICS: FINANCIALS
TABLE 101. ATARA BIOTHERAPEUTICS: PRODUCTS & SERVICES
TABLE 102. ATARA BIOTHERAPEUTICS: DEVELOPMENTS
TABLE 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS
TABLE 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES
TABLE 105. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS
TABLE 106. BLUEBIRD BIO, INC.: FINANCIALS
TABLE 107. BLUEBIRD BIO, INC.: PRODUCTS & SERVICES
TABLE 108. BLUEBIRD BIO, INC.: RECENT DEVELOPMENTS
TABLE 109. DENDREON CORP.: FINANCIALS
TABLE 110. DENDREON CORP.: PRODUCTS & SERVICES
TABLE 111. DENDREON CORP.: RECENT DEVELOPMENTS
Charts
CHART. 1. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 2. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ALLOGENEIC THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 3. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR AUTOLOGOUS THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 4. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 5. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 6. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR CARDIOVASCULAR DISEASE (CVD), BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 7. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 8. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR DERMATOLOGY,2021-2030 (USD BILLION)
CHART. 9. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 10. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 11. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 12. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 13. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 14. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 15. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 16. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 17. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 18. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 19. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 20. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 21. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 22. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 23. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 24. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 25. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 26. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 27. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 28. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 29. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 30. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 31. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 32. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 33. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 34. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 35. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 36. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 37. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 38. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 39. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 40. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 41. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 42. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 43. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 44. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 45. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 46. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 47. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 48. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 49. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 50. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 51. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 52. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 53. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 54. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 55. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 56. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 57. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 58. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 59. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 60. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 61. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 62. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 63. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 64. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 65. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 66. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 67. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 68. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 69. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 70. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 71. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 72. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 73. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 74. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 75. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 76. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 77. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 78. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 79. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 80. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 81. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 82. NOVARTIS AG: FINANCIALS
CHART. 83. NOVARTIS AG: PRODUCTS & SERVICES
CHART. 84. NOVARTIS AG: RECENT DEVELOPMENTS
CHART. 85. GILEAD SCIENCES, INC.: FINANCIALS
CHART. 86. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES
CHART. 87. GILEAD SCIENCES, INC.: RECENT DEVELOPMENTS
CHART. 88. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
CHART. 89. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
CHART. 90. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
CHART. 91. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS
CHART. 92. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES
CHART. 93. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS
CHART. 94. JCR PHARMACEUTICALS CO., LTD.: FINANCIALS
CHART. 95. JCR PHARMACEUTICALS CO., LTD.: PRODUCTS & SERVICES
CHART. 96. JCR PHARMACEUTICALS CO., LTD.: RECENT DEVELOPMENTS
CHART. 97. TEGO SCIENCE: FINANCIALS
CHART. 98. TEGO SCIENCE: PRODUCTS & SERVICES
CHART. 99. TEGO SCIENCE: RECENT DEVELOPMENTS
CHART. 100. ATARA BIOTHERAPEUTICS: FINANCIALS
CHART. 101. ATARA BIOTHERAPEUTICS: PRODUCTS & SERVICES
CHART. 102. ATARA BIOTHERAPEUTICS: DEVELOPMENTS
CHART. 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS
CHART. 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES
CHART. 105. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS
CHART. 106. BLUEBIRD BIO, INC.: FINANCIALS
CHART. 107. BLUEBIRD BIO, INC.: PRODUCTS & SERVICES
CHART. 108. BLUEBIRD BIO, INC.: RECENT DEVELOPMENTS
CHART. 109. DENDREON CORP.: FINANCIALS
CHART. 110. DENDREON CORP.: PRODUCTS & SERVICES
CHART. 111. DENDREON CORP.: RECENT DEVELOPMENTS
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. THERAPY TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Allogeneic Therapies
5.3. Autologous Therapies
6. THERAPEUTIC AREA: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Oncology
6.3. Cardiovascular Disease (CVD)
6.4. Musculoskeletal Disorders
6.5. Dermatology
6.6. Others
7. GEOGRAPHY: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. North America (U.S., Mexico, Canada)
7.3. Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia, Rest of Europe)
7.4. Asia Pacific (Japan, China, India, Australia, South East Asia, Rest of APAC)
7.5. Latin America (Brazil, Argentina)
7.6. Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East and Africa)
8. COMPETITIVE LANDSCAPE
8.1. Competitor Comparison Analysis
8.2. Market Developments
8.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
8.2.2. Product Launches and execution
9. VENDOR PROFILES
9.1. Novartis AG
9.1.1. Overview
9.1.2. Financial Overview
9.1.3. Product Offerings
9.1.4. Developments
9.1.5. Business Strategy
9.2. Gilead Sciences, Inc.
9.2.1. Overview
9.2.2. Financial Overview
9.2.3. Product Offerings
9.2.4. Developments
9.2.5. Business Strategy
9.3. Bristol-Myers Squibb Company
9.3.1. Overview
9.3.2. Financial Overview
9.3.3. Product Offerings
9.3.4. Developments
9.3.5. Business Strategy
9.4. Johnson & Johnson Services, Inc
9.4.1. Overview
9.4.2. Financial Overview
9.4.3. Product Offerings
9.4.4. Developments
9.4.5. Business Strategy
9.5. JCR Pharmaceuticals Co., Ltd.
9.5.1. Overview
9.5.2. Financial Overview
9.5.3. Product Offerings
9.5.4. Developments
9.5.5. Business Strategy
9.6. Tego Science
9.6.1. Overview
9.6.2. Financial Overview
9.6.3. Product Offerings
9.6.4. Developments
9.6.5. Business Strategy
9.7. Atara Biotherapeutics
9.7.1. Overview
9.7.2. Financial Overview
9.7.3. Product Offerings
9.7.4. Developments
9.7.5. Business Strategy
9.8. Takeda Pharmaceutical Company Limited
9.8.1. Overview
9.8.2. Financial Overview
9.8.3. Product Offerings
9.8.4. Developments
9.8.5. Business Strategy
9.9. Bluebird Bio, Inc.
9.9.1. Overview
9.9.2. Financial Overview
9.9.3. Product Offerings
9.9.4. Developments
9.9.5. Business Strategy
9.10. Dendreon Corp.
9.10.1. Overview
9.10.2. Financial Overview
9.10.3. Product Offerings
9.10.4. Developments
9.10.5. Business Strategy
10. ANALYST OPINION
11. ANNEXURE
11.1. Report Scope
11.2. Market Definitions
11.3. Research Methodology
11.3.1. Data Collation and In-house Estimation
11.3.2. Market Triangulation
11.3.3. Forecasting
11.4. Report Assumptions
11.5. Declarations
11.6. Stakeholders
11.7. Abbreviations
Tables
TABLE 1. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 2. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ALLOGENEIC THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 3. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR AUTOLOGOUS THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 5. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR CARDIOVASCULAR DISEASE (CVD), BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 7. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 8. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR DERMATOLOGY,2021-2030 (USD BILLION)
TABLE 9. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 11. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 12. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 13. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 14. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 15. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 16. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 17. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 18. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 19. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 20. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 21. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 22. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 23. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 24. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 25. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 26. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 27. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 28. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 29. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 30. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 31. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 32. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 33. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 34. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 35. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 36. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 37. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 38. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 39. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 40. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 41. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 42. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 43. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 44. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 45. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 46. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 47. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 48. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 49. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 50. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 51. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 52. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 53. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 54. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 55. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 56. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 57. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 58. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 59. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 60. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 61. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 62. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 63. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 64. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 65. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 66. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 67. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 68. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 69. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 70. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 71. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 72. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 73. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 74. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 75. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 76. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 77. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 78. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 79. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
TABLE 80. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
TABLE 81. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
TABLE 82. NOVARTIS AG: FINANCIALS
TABLE 83. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 84. NOVARTIS AG: RECENT DEVELOPMENTS
TABLE 85. GILEAD SCIENCES, INC.: FINANCIALS
TABLE 86. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES
TABLE 87. GILEAD SCIENCES, INC.: RECENT DEVELOPMENTS
TABLE 88. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 89. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 90. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 91. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS
TABLE 92. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES
TABLE 93. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS
TABLE 94. JCR PHARMACEUTICALS CO., LTD.: FINANCIALS
TABLE 95. JCR PHARMACEUTICALS CO., LTD.: PRODUCTS & SERVICES
TABLE 96. JCR PHARMACEUTICALS CO., LTD.: RECENT DEVELOPMENTS
TABLE 97. TEGO SCIENCE: FINANCIALS
TABLE 98. TEGO SCIENCE: PRODUCTS & SERVICES
TABLE 99. TEGO SCIENCE: RECENT DEVELOPMENTS
TABLE 100. ATARA BIOTHERAPEUTICS: FINANCIALS
TABLE 101. ATARA BIOTHERAPEUTICS: PRODUCTS & SERVICES
TABLE 102. ATARA BIOTHERAPEUTICS: DEVELOPMENTS
TABLE 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS
TABLE 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES
TABLE 105. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS
TABLE 106. BLUEBIRD BIO, INC.: FINANCIALS
TABLE 107. BLUEBIRD BIO, INC.: PRODUCTS & SERVICES
TABLE 108. BLUEBIRD BIO, INC.: RECENT DEVELOPMENTS
TABLE 109. DENDREON CORP.: FINANCIALS
TABLE 110. DENDREON CORP.: PRODUCTS & SERVICES
TABLE 111. DENDREON CORP.: RECENT DEVELOPMENTS
Charts
CHART. 1. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 2. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ALLOGENEIC THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 3. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR AUTOLOGOUS THERAPIES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 4. CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 5. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 6. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR CARDIOVASCULAR DISEASE (CVD), BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 7. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 8. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR DERMATOLOGY,2021-2030 (USD BILLION)
CHART. 9. CELL THERAPY TECHNOLOGIES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
CHART. 10. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 11. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 12. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 13. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 14. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 15. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 16. U.S CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 17. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 18. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 19. CANADA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 20. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 21. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 22. MEXICO CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 23. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 24. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 25. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 26. EUROPE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 27. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 28. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 29. GERMANY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 30. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 31. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 32. U.K CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 33. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 34. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 35. FRANCE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 36. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 37. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 38. ITALY CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 39. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 40. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 41. SPAIN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 42. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 43. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 44. ROE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 45. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
CHART. 46. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 47. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 48. ASIA PACIFIC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 49. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 50. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 51. CHINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 52. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 53. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 54. INDIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 55. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 56. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 57. JAPAN CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 58. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 59. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 60. REST OF APAC CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 61. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 62. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 63. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 64. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 65. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 66. BRAZIL CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 67. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 68. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 69. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 70. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 71. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 72. MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 73. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 74. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 75. SAUDI ARABIA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 76. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 77. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 78. UAE CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 79. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPY TYPE, 2021-2030 (USD BILLION)
CHART. 80. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY THERAPEUTIC AREA, 2021-2030 (USD BILLION)
CHART. 81. REST OF MIDDLE EAST AND AFRICA CELL THERAPY TECHNOLOGIES MARKET VALUE, BY REGION, 2021-2030 (USD BILLION)
CHART. 82. NOVARTIS AG: FINANCIALS
CHART. 83. NOVARTIS AG: PRODUCTS & SERVICES
CHART. 84. NOVARTIS AG: RECENT DEVELOPMENTS
CHART. 85. GILEAD SCIENCES, INC.: FINANCIALS
CHART. 86. GILEAD SCIENCES, INC.: PRODUCTS & SERVICES
CHART. 87. GILEAD SCIENCES, INC.: RECENT DEVELOPMENTS
CHART. 88. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
CHART. 89. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
CHART. 90. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
CHART. 91. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS
CHART. 92. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES
CHART. 93. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS
CHART. 94. JCR PHARMACEUTICALS CO., LTD.: FINANCIALS
CHART. 95. JCR PHARMACEUTICALS CO., LTD.: PRODUCTS & SERVICES
CHART. 96. JCR PHARMACEUTICALS CO., LTD.: RECENT DEVELOPMENTS
CHART. 97. TEGO SCIENCE: FINANCIALS
CHART. 98. TEGO SCIENCE: PRODUCTS & SERVICES
CHART. 99. TEGO SCIENCE: RECENT DEVELOPMENTS
CHART. 100. ATARA BIOTHERAPEUTICS: FINANCIALS
CHART. 101. ATARA BIOTHERAPEUTICS: PRODUCTS & SERVICES
CHART. 102. ATARA BIOTHERAPEUTICS: DEVELOPMENTS
CHART. 103. TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIALS
CHART. 104. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS & SERVICES
CHART. 105. TAKEDA PHARMACEUTICAL COMPANY LIMITED: RECENT DEVELOPMENTS
CHART. 106. BLUEBIRD BIO, INC.: FINANCIALS
CHART. 107. BLUEBIRD BIO, INC.: PRODUCTS & SERVICES
CHART. 108. BLUEBIRD BIO, INC.: RECENT DEVELOPMENTS
CHART. 109. DENDREON CORP.: FINANCIALS
CHART. 110. DENDREON CORP.: PRODUCTS & SERVICES
CHART. 111. DENDREON CORP.: RECENT DEVELOPMENTS
